Baudax Bio, Inc. Quarterly report pursuant to Section 13 or 15(d)

Quarterly report pursuant to Section 13 or 15(d)

Consolidated and Combined Statements of Shareholders' Equity (Unaudited)

Consolidated and Combined Statements of Shareholders' Equity (Unaudited) - USD ($) $ in Thousands	Total	Public Offering	Equity Facility	Separation	Recro	Common Stock	Common Stock Public Offering	Common Stock Equity Facility	Common Stock Separation	Additional Paid in Capital	Additional Paid in Capital Public Offering	Additional Paid in Capital Equity Facility	Additional Paid in Capital Recro	Accumulated Deficit
Balance at Dec. 31, 2018	$ (68,347)
Net loss	(4,335)
Net transfer from parent	19,823
Parent allocation - share-based compensation	1,527
Balance at Mar. 31, 2019	(51,332)
Balance at Dec. 31, 2018	(68,347)
Net loss	(14,917)
Balance at Jun. 30, 2019	(29,187)
Balance at Mar. 31, 2019	(51,332)
Net loss	(10,582)
Net transfer from parent	31,052
Parent allocation - share-based compensation	1,675
Balance at Jun. 30, 2019	(29,187)
Balance at Dec. 31, 2019	(16,721)					$ 94				$ 19,405				$ (36,220)
Balance, Shares at Dec. 31, 2019						9,350,709
Stock-based compensation expense	2,177				$ 456					2,177			$ 456
Issuance of common stock		$ 14,976	$ 3,612	$ 1			$ 77	$ 4	$ 1		$ 14,899	$ 3,608
Issuance of common stock, Shares							7,692,308	441,967	45,874
Issuance of restricted stock units, net of shares withheld for income taxes	(95)									(95)
Issuance of restricted stock units, net of shares withheld for income taxes, Shares						39,130
Net loss	(40,298)													(40,298)
Balance at Mar. 31, 2020	(35,892)					$ 176				40,450				(76,518)
Balance, Shares at Mar. 31, 2020						17,569,988
Balance at Dec. 31, 2019	(16,721)					$ 94				19,405				(36,220)
Balance, Shares at Dec. 31, 2019						9,350,709
Net loss	(70,743)
Balance at Jun. 30, 2020	(59,404)					$ 184				47,375				(106,963)
Balance, Shares at Jun. 30, 2020						18,374,604
Balance at Mar. 31, 2020	(35,892)					$ 176				40,450				(76,518)
Balance, Shares at Mar. 31, 2020						17,569,988
Stock-based compensation expense	1,864				$ 445					1,864			$ 445
Stock issuance costs	(3)									(3)
Warrants issued in connection with financing facility	1,423									1,423
Exercise of warrants	3,204					$ 8				3,196
Exercise of warrants, Shares						804,616
Net loss	(30,445)													(30,445)
Balance at Jun. 30, 2020	$ (59,404)					$ 184				$ 47,375				$ (106,963)
Balance, Shares at Jun. 30, 2020						18,374,604